Aion Therapeutic Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023
For the nine months, net income was CAD 0.466792 million compared to net loss of CAD 2.2 million a year ago. Basic earnings per share from continuing operations was CAD 0.003 compared to basic loss per share from continuing operations of CAD 0.016 a year ago. Diluted earnings per share from continuing operations was CAD 0.003 compared to diluted loss per share from continuing operations of CAD 0.016 a year ago.